Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $62 at SVB Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wall Street ends lower as Middle East tensions escalate
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $55 at Morgan Stanley
July 15, 2019 8:46 AM EDTMorgan Stanley analyst Matthew Harrison lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $55.00 (from $57.00) while maintaining a Equalweight rating.
... MoreBiohaven (BHVN) Reports Publication of Positive Phase 3 Trial of Rimegepant Zydis
July 15, 2019 7:32 AM EDTBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announces that The Lancet published online positive results from a Phase 3 pivotal clinical trial of rimegepant Zydis® orally dissolving tablet (ODT) for the acute treatment of migraine. These data show that compared to placebo, patients treated with a single dose of the rimegepant ODT formulation experienced rapid and sustained clinical benefits.
"The results from this pivotal Phase 3 study show the... More
